Nice | Tolvaptan for treating autosomal polycystic kidney disease

15th February 2016 by Louise Hudman

Nice | Tolvaptan for treating autosomal polycystic kidney disease

This is a new guideline from NICE advising that tolvaptan can be used for treating autosomal polycystic kidney disease. It is a selective vasopressin antagonist which can reduce cell proliferation, cyst formation and fluid excretion. This reduces kidney growth and protects renal function.

Patients need to have:

  • CKD 2 or 3
  • Rapidly progressing disease

It has several side-effects, including polyuria, nocturia and frequency of urination. It can also be hepatotoxic and can elevate liver function tests.

MIMS Learning | Chronic kidney disease: clinical review

Join

Join to view the rest of this content, as well as access all the benefits of joining NASGP.

Join

Login

Already a member? Login to view this content.

Login

"LocumDeck is so good and so intuitive that I am lost for words and utterly filled with glee.

It can send an email confirming the sessions that are booked and creates and emails invoices direct to the practice for you. These contain links to your beautifully laid out ‘credentials’ page with all your relevant documents, and a model contract that is all ready for you to accept or edit.

It automatically produces and sends the locum form A, and will produce locum form B. It also acts as the calendar... And it all happens automatically. It is really less than a minute to invoice and do the pension forms, with everything calculated perfectly."

Dr Annette Steele

See the full list of features within our NASGP membership plans

Membership